−0.75 TRY
25.87 M TRY
1.45 B TRY
24.45 M
About MEDITERA TIBBI MALZEME
Sector
Industry
Headquarters
Karabaglar
Website
Founded
1996
ISIN
TREMDTR00028
FIGI
BBG011J5DGS4
Meditera Tibbi Malzeme Sanayi ve Ticaret AS engages in manufacturing medical devices. The company was founded on February 14, 1996 and is headquartered in Karabaglar, Turkey.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MEDTR is 50.75 TRY — it has decreased by −0.29% in the past 24 hours. Watch MEDITERA TIBBI MALZEME stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIST exchange MEDITERA TIBBI MALZEME stocks are traded under the ticker MEDTR.
MEDTR stock has fallen by −3.69% compared to the previous week, the month change is a 21.31% rise, over the last year MEDITERA TIBBI MALZEME has showed a 30.66% increase.
We've gathered analysts' opinions on MEDITERA TIBBI MALZEME future price: according to them, MEDTR price has a max estimate of 65.00 TRY and a min estimate of 65.00 TRY. Watch MEDTR chart and read a more detailed MEDITERA TIBBI MALZEME stock forecast: see what analysts think of MEDITERA TIBBI MALZEME and suggest that you do with its stocks.
MEDTR reached its all-time high on Nov 5, 2024 with the price of 53.00 TRY, and its all-time low was 8.70 TRY and was reached on Jul 14, 2021. View more price dynamics on MEDTR chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MEDTR stock is 6.15% volatile and has beta coefficient of −0.11. Track MEDITERA TIBBI MALZEME stock price on the chart and check out the list of the most volatile stocks — is MEDITERA TIBBI MALZEME there?
Yes, you can track MEDITERA TIBBI MALZEME financials in yearly and quarterly reports right on TradingView.
MEDITERA TIBBI MALZEME revenue for the last quarter amounts to 370.00 M TRY, despite the estimated figure of 402.00 M TRY. In the next quarter, revenue is expected to reach 495.00 M TRY.
MEDTR net income for the last quarter is 27.07 M TRY, while the quarter before that showed 10.60 M TRY of net income which accounts for 155.33% change. Track more MEDITERA TIBBI MALZEME financial stats to get the full picture.
Yes, MEDTR dividends are paid annually. The last dividend per share was 0.29 TRY. As of today, Dividend Yield (TTM)% is 0.58%. Tracking MEDITERA TIBBI MALZEME dividends might help you take more informed decisions.
MEDITERA TIBBI MALZEME dividend yield was 1.06% in 2023, and payout ratio reached 135.29%. The year before the numbers were 3.15% and 50.50% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 11, 2024, the company has 728.00 employees. See our rating of the largest employees — is MEDITERA TIBBI MALZEME on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDITERA TIBBI MALZEME EBITDA is 374.96 M TRY, and current EBITDA margin is 23.07%. See more stats in MEDITERA TIBBI MALZEME financial statements.
Like other stocks, MEDTR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDITERA TIBBI MALZEME stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDITERA TIBBI MALZEME technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDITERA TIBBI MALZEME stock shows the buy signal. See more of MEDITERA TIBBI MALZEME technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.